drugset / Trial / NCT06672276

To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency

NCT06672276

Phase 1 Completed 32 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study is an open, parallel, single-dose phase I clinical study to evaluate the pharmacokinetics and safety of TQD3606 for injection in subjects with renal insufficiency.

Timeline

Start
2024-11-20
Primary completion
2025-05-06
Completion
2025-05-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Meropenem Small molecule
Comparator avibactam Small molecule

Indications

No indication recorded.